UCSF Center for Synthetic Immunology: Tools to Reprogram the Immune System to Combat Cancer
Project Number1U54CA244438-01
Contact PI/Project LeaderLIM, WENDELL A
Awardee OrganizationUNIVERSITY OF CALIFORNIA, SAN FRANCISCO
Description
Abstract Text
Project Summary/Abstract
UCSF Center for Synthetic Immunology: Tools to Reprogram the Immune System to Combat Cancer
The immune system has emerged as an extraordinarily powerful tool for combating cancer. One of the most
potent agents are engineered T cells programmed to recognize and kill tumor cells. Nonetheless, our ability to
engineer T cells and other immune cells and program them to execute new functions remains relatively
primitive. Aside from CAR T cells for treatment of blood cancers, most engineered cell therapies are risky,
potentially highly toxic, unreliable and often ineffective, especially those cell therapies that attempt to target
solid cancers. We hypothesize that to fulfil the promise of engineered immune cell therapies, we must first
transform cell engineering into a systematic and predictable process; one that uses reliable technology
platforms and principles. Our center will focus on developing a set of sophisticated immune engineering
platforms that address three major needs in next-generation cell therapies:
1) Smart recognition of cancer – develop antigen-pattern recognition circuits that direct immune cells to
optimally recognize solid tumors and discriminate against normal tissue crossreaction, guided by
computational bioinformatic analysis of gene expression patterns.
2) Overcoming the tumor microenvironment – develop multiple classes of cellular circuits that can
overcome or locally remodel immune-suppressive tumor microenvironments to promote highly efficient
therapeutic immune cell trafficking, proliferation, persistence, and tumor-killing activity
3) User-control and safety – to increase control over and safety of these powerful engineered cells, we will
develop a suite of ways to communicate with and control the activity of engineered immune cells in vivo,
including nano/microparticles and small molecules.
To achieve these goals, we have assembled the UCSF Center for Synthetic Immunology, a tightly
integrated interdisciplinary team that encompasses synthetic biologists, immunologists, bio-informaticists,
control engineers, and materials scientists. The products of this center will include publicly available toolkits of
parts and circuits for cell engineering, high-throughput platforms for rapid circuit assembly, new programmable
nanomaterials for controlling immune cell behavior, searchable bioinformatic databases for optimization of
tumor recognition, and computational frameworks for circuit design and for modeling/prototyping in vivo circuit
function. These platforms will help to advance immune cell engineering to be far more reliable, predictable,
effective and safe.
Public Health Relevance Statement
Project Narrative
The outcomes of this proposed research will dramatically improve our ability to reliably engineer immune cells
to safely, effectively and precisely treat a broad range of cancers, including solid tumors
National Institute of Biomedical Imaging and Bioengineering
$2,396,457
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1U54CA244438-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1U54CA244438-01
Patents
No Patents information available for 1U54CA244438-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1U54CA244438-01
Clinical Studies
No Clinical Studies information available for 1U54CA244438-01
News and More
Related News Releases
No news release information available for 1U54CA244438-01
History
No Historical information available for 1U54CA244438-01
Similar Projects
No Similar Projects information available for 1U54CA244438-01